Adaptive Biotechnologies Corporation
25.51USD
+1.1000 (+4.51%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ADPT.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 185.3M | 170.3M | 179.0M | 277.0M | 290.9M | 357.7M |
| Q1 | 38.6M | 37.6M | 41.9M | 52.4M | 70.9M | — |
| Q2 | 43.7M | 48.9M | 43.2M | 58.9M | 71.6M | — |
| Q3 | 47.8M | 37.9M | 46.4M | 94.0M | 71.2M | — |
| Q4 | 55.2M* | 45.8M* | 47.5M* | 71.7M* | 79.4M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.40 | -1.56 | -1.08 | -.390 | -.542 | -.180 |
| Q1 | -.440 | -.400 | -.330 | -.200 | -.130 | — |
| Q2 | -.370 | -.330 | -.310 | -.170 | -.250 | — |
| Q3 | -.320 | -.350 | -.220 | .060 | -.096 | — |
| Q4 | -.282* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.481* |
| -.229* |
| -.089* |
| -.064 |
| — |
Debt level and coverage